PCM
SRPT icon

Peregrine Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Peregrine Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-866
Closed -$14.8K – 352
2025
Q2 		$14.8K Sell
866
-68,008
-99% -$2.9M ﹤0.01% 316
2025
Q1 		$4.4M Buy
68,874
+15,070
+28% +$1.59M 0.15% 219
2024
Q4 		$6.54M Buy
53,804
+11,965
+29% +$1.47M 0.19% 155
2024
Q3 		$5.23M Buy
41,839
+5,545
+15% +$767K 0.16% 210
2024
Q2 		$5.73M Buy
36,294
+780
+2% +$100K 0.17% 210
2024
Q1 		$4.6M Sell
35,514
-2,949
-8% -$361K 0.13% 240
2023
Q4 		$3.71M Sell
38,463
-6,715
-15% -$644K 0.11% 240
2023
Q3 		$5.48M Buy
45,178
+5,166
+13% +$584K 0.16% 226
2023
Q2 		$4.58M Sell
40,012
-30,565
-43% -$3.94M 0.12% 243
2023
Q1 		$9.73M Buy
70,577
+5,576
+9% +$723K 0.28% 146
2022
Q4 		$8.42M Sell
65,001
-9,338
-13% -$1.08M 0.26% 176
2022
Q3 		$8.22M Sell
74,339
-21,825
-23% -$2.2M 0.27% 178
2022
Q2 		$7.21M Sell
96,164
-74
-0.1% -$5.44K 0.22% 209
2022
Q1 		$7.52M Buy
+96,238
New +$7.37M 0.18% 223

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Peregrine Capital Management's SRPT Position: Q3 2025 in Review

Peregrine Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 866 shares — an estimated $14.8K sold.

Peregrine Capital Management first reported a position in SRPT in Q1 2022 and held it in 14 quarters. The position peaked at $9.73M in Q1 2023. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Peregrine Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Peregrine Capital Management sold 866 Sarepta Therapeutics shares in Q3 2025, an estimated $14.8K.
  • Peregrine Capital Management first reported a position in Sarepta Therapeutics in Q1 2022 and held it in 14 quarters.
  • Peregrine Capital Management's Sarepta Therapeutics position peaked at $9.73M in Q1 2023.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Peregrine Capital Management's 13F filing for Q3 2025, filed 23 Oct 2025.